| Portfolio Inside Human Genome's
Earnings
[08/05/00]
Revenues
declined and net loss skyrocketed from a year ago,
but does this quarter's numbers really matter?
RIMM: The Stock
that Can't Catch a Break
[07/01/00]
With a stock
price down 80% off its highs, investors are
wondering if their new spending plan is way to
grow the company for the future.
BLyS Enters Clincal
Trials
[06/27/00]
Human Genome
Sciences has announced it will send its fourth
genomics-derived drug into clinical drug trials.
Find out what BlyS could mean to the future of
the company.
More Maria on HGSI
[06/03/00]
In part two of
our series, we take a look at the interview
between Maria Bartiromo and portfolio manager
Faraz Naqvi about Human Genome.
Maria Interviews
Human Genome
[05/31/00]
Maria
Bartiromo recently interviewed William Haseltine,
CEO of Human Genome Sciences, about the company
and its future in the biotech field.
Performance
As of
4:00 PM; 06/27/00
| Date |
Stock |
Shares |
Cost/Share |
Price |
% Change |
| 02/22/00 |
HGSI |
3 |
204.15 |
134 1/32 |
-34.35% |
| 02/25/00 |
RIMM |
4 |
144.30 |
42 1/2 |
-70.55% |
| Date |
Stock |
Shares |
Cost |
Value |
Change |
| 02/22/00 |
HGSI |
3 |
612.45 |
402.09 |
-210.36 |
| 02/25/00 |
RIMM |
4 |
577.20 |
170.00 |
-407.20 |
| Indices |
Start Value |
Current Val |
% Change |
Annualized |
| StockChamp |
1339.49 |
721.93 |
-46.10% |
---
|
| Dow Indust. |
10219.83 |
10504.46 |
2.79% |
---
|
| Nasdaq |
4432.83 |
3858.96 |
-12.95% |
---
|
| S&P 500 |
1347.37 |
1450.55 |
7.66% |
---
|
Portfolio
Breakdown
Stock Value: $572.09
Cash Value: $149.84
|